This inhibitor increased apoptosis of primary CLL B-cells, even if the patient had high risk factors (e.g., 17p/P53 deletions) or progressed on other agents including ibrutinib [67,70]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.